Nanopreparations to overcome multidrug resistance in cancer

被引:279
作者
Patel, Niravkumar R. [1 ]
Pattni, Bhushan S. [1 ]
Abouzeid, Abraham H. [1 ]
Torchilin, Vladimir P. [1 ]
机构
[1] Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA
关键词
Nanopreparations; Multidrug resistance; Spheroid culture; Combination therapy; CELL LUNG-CANCER; SURVIVIN SPLICE VARIANTS; POLYELECTROLYTE COMPLEX MICELLES; NANOPARTICULATE DELIVERY-SYSTEM; EPITHELIAL OVARIAN-CANCER; ATP-BINDING-CASSETTE; MDR1; GENE-EXPRESSION; DRUG-RESISTANCE; BREAST-CANCER; P-GLYCOPROTEIN;
D O I
10.1016/j.addr.2013.08.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug resistance is the most widely exploited phenomenon by which cancer eludes chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over-expression of efflux transporters, defective apoptotic machineries, and altered molecular targets, to the physiological factors such as higher interstitial fluid pressure, low extracellular pH, and formation of irregular tumor vasculature are responsible for multidrug resistance. A combination of various undesirable factors associated with biological surroundings together with poor solubility and instability of many potential therapeutic small & large molecules within the biological systems and systemic toxicity of chemotherapeutic agents has necessitated the need for nano-preparations to optimize drug delivery. The physiology of solid tumors presents numerous challenges for successful therapy. However, it also offers unique opportunities for the use of nanotechnology. Nanoparticles, up to 400 nm in size, have shown great promise for carrying, protecting and delivering potential therapeutic molecules with diverse physiological properties. In this review, various factors responsible for the MDR and the use of nanotechnology to overcome the MDR, the use of spheroid culture as well as the current technique of producing microtumor tissues in vitro are discussed in detail. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1748 / 1762
页数:15
相关论文
共 241 条
  • [1] Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer
    Abbasi, Meysam
    Lavasanifar, Afsaneh
    Uludag, Hasan
    [J]. MEDICINAL RESEARCH REVIEWS, 2013, 33 (01) : 33 - 53
  • [2] Abolhoda A, 1999, CLIN CANCER RES, V5, P3352
  • [3] Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model
    Abu Lila, Amr S.
    Kizuki, Shinji
    Doi, Yusuke
    Suzuki, Takuya
    Ishida, Tatsuhiro
    Kiwada, Hiroshi
    [J]. JOURNAL OF CONTROLLED RELEASE, 2009, 137 (01) : 8 - 14
  • [4] Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells
    Ajabnoor, G. M. A.
    Crook, T.
    Coley, H. M.
    [J]. CELL DEATH & DISEASE, 2012, 3 : e260 - e260
  • [5] Allen JD, 2000, CANCER RES, V60, P5761
  • [6] Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy
    Ambasta, Rashmi K.
    Sharma, Archita
    Kumar, Pravir
    [J]. VASCULAR CELL, 2011, 3
  • [7] Targeting death and decoy receptors of the tumour-necrosis factor superfamily
    Ashkenazi, A
    [J]. NATURE REVIEWS CANCER, 2002, 2 (06) : 420 - 430
  • [8] Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types
    Bae, Sungho
    Ma, Kyungwan
    Kim, Tae Hyung
    Lee, Eun Seong
    Oh, Kyung Taek
    Park, Eun-Seok
    Lee, Kang Choon
    Youn, Yu Seok
    [J]. BIOMATERIALS, 2012, 33 (05) : 1536 - 1546
  • [9] In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA
    Bartholomeusz, Geoffrey
    Cherukuri, Paul
    Kingston, John
    Cognet, Laurent
    Lemos, Robert, Jr.
    Leeuw, Tonya K.
    Gumbiner-Russo, Laura
    Weisman, R. Bruce
    Powis, Garth
    [J]. NANO RESEARCH, 2009, 2 (04) : 279 - 291
  • [10] Bates S, 2001, CANCER-AM CANCER SOC, V92, P1577, DOI 10.1002/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO